Effect of Air Pollution on the Cognitive Function of Adolescents (ATENC!Ó)

June 11, 2025 updated by: Barcelona Institute for Global Health

Citizen Science for Analysing the Effect of Air Pollution on the Cognitive Function of Adolescents

Previous observational studies have reported an association between higher air pollution exposure and lower attention in children. With this project, the investigators aim to confirm this association in adolescents using an experimental design. In addition, the study will assess the relationship between air pollution exposure and individual preferences with respect to risk, time and social considerations. High school students in 3rd grade (ESO, 14-15 years of age) in different high schools in the Barcelona province (Spain) will be invited to participate. For each class in each high school, participating students will be randomly split into two equal-sized groups. Each group will be assigned to a different classroom where they will complete several activities during two hours, including an attention test (Flanker task) and a reduced version of the Global Preferences Survey. One of the classrooms will have an air purifier that will clean the air. The other classroom will have the same device but without the filters, so it will only re-circulate the air without cleaning it. Students will be masked to intervention allocation. The investigators hypothesize that students assigned to the clean air classroom will have better scores in the attention test, and that decision-making will also present differences in the two classrooms.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
2123

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Barcelona, Spain, 08003
        • ISGlobal

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

13 years to 16 years (Child)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Students in the 3rd ESO course in participating high schools with signed informed consent

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Purified air
Purifying the air with a Pure Airbox device (Zonair 3D). Use of air purifier (Pure Airbox, Zonair 3D) in the classroom 30 minutes before the participants enter the room and during the 2 hours of the experiment.
Other: Purifying the air with a Pure Airbox device (Zonair 3D)
Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
Other Names:
  • Air filtering
  • Air cleaning
Sham Comparator: Normal air
Using a sham air purifier (same device without filters). Use of the same air purifier but without filters, so that it only recirculates the air without purifying it. Used for the same time period than the other arm.
Other: Using a sham air purifier (same device without filters)
Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
Other Names:
  • Sham air cleaner

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Response Speed Consistency Throughout the Attention Network Task-Flanker Task (Post ANT)
Time Frame: Obtained from a test administered approximately 90 minutes after entering the classroom

This is a measure related to attentiveness that is calculated as hit reaction time standard error for correct responses (HRT-SE).

A higher HRT-SE indicates highly variable reactions during the ANT test that is related to inattentiveness.

A lower HRT-SE indicates indicates consistent reaction times and thus, a better attention performance.
Obtained from a test administered approximately 90 minutes after entering the classroom
Combined Risk Taking Score
Time Frame: Obtained from a test administered approximately 100 minutes after entering the classroom
The "Combined risk taking score" measures how willing the person is to take risks and is calculated as 0.4729985 × "Risk preference score" + 0.5270015 × "Willingness to take risks", as defined in Falk et al (2018). The "Combined risk taking score" is a weighted average of two z-scores ("risk preference score" and "willingness to take risks" score), and therefore it can be interpreted as a z-score. The central value of "Combined risk taking score" is 0 and represents the population mean. The higher the values of the "Combined risk taking score", the more willing is the person to take risks. The "Risk preference score" is the final node in the risk tree (see the online appendix of Falk et al (2018)), which is a value between 1 and 32, ranked by the level of risk aversion, which was then transformed to a z-score. The "Willingness to take risks" refers to the answer to the question on one's willingness to take risks, with values from 0 to 10), which was then transformed to a z-score.
Obtained from a test administered approximately 100 minutes after entering the classroom
Combined Patience Score
Time Frame: Obtained from a test administered approximately 100 minutes after entering the classroom
The "Combined patience score" measures the patience of the person and is calculated as 0.7115185 × "Time preference score" + 0.2884815 × "Self assessment of patience", as defined in Falk et al (2018). The "Combined patience score" is a weighted average of two z-scores ("time preference score" and "self assessment of patience" score), and therefore it can be interpreted as a z-score. The central value of "Combined patience score" is 0 and represents the population mean. The higher the values of the "Combined patience score" the more patience the person has. The "Time preference score" was obtained from the final node in the time tree (see the online appendix of Falk et al (2018)), which is a value between 1 and 32, ranked by the level of patience, which was then transformed to a z-score. The "Self assessment of patience" score refers to the answer to the question on the self-assessment of patience, with values from 0 to 10, which was then transformed to a z-score.
Obtained from a test administered approximately 100 minutes after entering the classroom
Positive Reciprocity Score
Time Frame: Obtained from a test administered approximately 100 minutes after entering the classroom
The "Positive reciprocity score" measures positive reciprocity. A person with high reciprocity agrees with the statement "When someone does me a favor, I am willing to return it". The score is calculated as 0.4847038 × "Willingness to return favor" + 0.5152962 × "Size of gift", as defined in Falk et al (2018). The "Positive reciprocity score" is a weighted average of two z-scores ("willingness to return a favor" score and "size of gift" score), and therefore it can be interpreted as a z-score, with the central value of 0 representing the population mean. Higher values of the score imply more positive reciprocity. "Willingness to return favor" refers to the answer to the question on the willingness to return a favor, ranked from 0 to 10 and then transformed to a z-score. "Size of gift" refers to the answer to the question on the reported size of the gift that would return to a stranger, from a list of 7 possible values (from 0 to 30€, by 5€ steps), then transformed to a z-score.
Obtained from a test administered approximately 100 minutes after entering the classroom
Altruism Score
Time Frame: Obtained from a test administered approximately 100 minutes after entering the classroom
The "Altruism score" measures the altruism of a person and is calculated as 0.6350048 × "Willingness to give to good causes" + 0.3649952 × "Hypothetical donation", as defined in Falk et al (2018). The "Altruism score" is a weighted average of two z-scores ("willingness to give to good causes" score and "hypothetical donation" score), and therefore it can be interpreted as a z-score, with the central value of 0 representing the population mean. Higher values of the score imply more altruism. "Willingness to give to good causes" refers to the answer to the question on the willingness to give to good causes, ranked from 0 to 10 and then transformed to a z-score. "Hypothetical donation" refers to the answer to the question on the size of the hypothetical donation one would be willing to make, transformed to a z-score.
Obtained from a test administered approximately 100 minutes after entering the classroom
Trust Score
Time Frame: Obtained from a test administered approximately 100 minutes after entering the classroom
Answer to the question "I assume that people have only the best intentions", which is ranked from 0 to 10. Higher values imply more trust.
Obtained from a test administered approximately 100 minutes after entering the classroom

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Impulsivity (From ANT)
Time Frame: Obtained from a test administered approximately 90 minutes after entering the classroom
Number of incorrect responses (responses made in the opposite direction to the direction of the target arrow) Lower score indicates a better attention performance. Total range score: 0-38.
Obtained from a test administered approximately 90 minutes after entering the classroom
Selective Attention (From ANT)
Time Frame: Obtained from a test administered approximately 90 minutes after entering the classroom
Number of omission errors (failure to respond) Lower score indicates a better attention performance Total range score: 0-21. Higher values represent a worse outcome
Obtained from a test administered approximately 90 minutes after entering the classroom
Alerting Score (From ANT)
Time Frame: Obtained from a test administered approximately 90 minutes after entering the classroom
Alerting represents the ability to maintain a state of high vigilance to incoming stimuli It is calculated by subtracting the median reaction time for double cue from median reaction time for the no cue condition (calculations performed after removing the incongruent trials). A lower score indicates a better attention performance
Obtained from a test administered approximately 90 minutes after entering the classroom
Orienting Score (From ANT)
Time Frame: Obtained from a test administered approximately 90 minutes after entering the classroom
Orienting is the ability to select information and it is calculated by subtracting the median reaction time for spatial cue from the reaction time for central cue (calculations performed after removing the incongruent trials).A lower score indicates a better attention performance
Obtained from a test administered approximately 90 minutes after entering the classroom
Conflict Score (Executive Attention) (From ANT)
Time Frame: Obtained from a test administered approximately 90 minutes after entering the classroom
Conflict generally refers to the ability to monitor and resolve conflict among responses and in this study it is calculated as the median reaction time for each flanker condition (across cue conditions) and subtracting the congruent from the incongruent reaction times. A lower score indicates a better attention performance
Obtained from a test administered approximately 90 minutes after entering the classroom
Self Assessment of How Good They Are in Math
Time Frame: Obtained from a test administered approximately 100 minutes after entering the classroom
Answer to the question on math skills, ranging from 0 to 10. The higher the score, the better the person feels s/he is doing in math.
Obtained from a test administered approximately 100 minutes after entering the classroom

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Barcelona Institute for Global Health

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Recercaixa
Centre de Recerca per a l'Educació Científica i Matemàtica (CRECIM)
Institute of Environmental Assessment and Water Research (IDAEA-CSIC)
Economics and Bussiness Department, Universtitat Pompeu Fabra

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Xavier Basagaña, PhD, Barcelona Institute for Global Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 23, 2018

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 11, 2019

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 11, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 23, 2018

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 30, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 3, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 12, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 11, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • PI2030

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected IPD except identifying information for participants or high schools will be shared

IPD Sharing Time Frame

Data will become available when publishing the results in a scientific journal, with no time restrictions

IPD Sharing Access Criteria

Access to anyone via a public repository

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings